These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 30478168)

  • 61. Pharmacokinetics of and maintenance dose recommendations for vancomycin in severe pneumonia patients undergoing continuous venovenous hemofiltration with the combination of predilution and postdilution.
    Li Q; Liang F; Sang L; Li P; Lv B; Tan L; Liu X; Chen W
    Eur J Clin Pharmacol; 2020 Feb; 76(2):211-217. PubMed ID: 31734748
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Continuous renal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review.
    Honoré PM; Jacobs R; Joannes-Boyau O; Lochy S; Boer W; De Waele E; Van Gorp V; De Regt J; Collin V; Spapen HD
    Blood Purif; 2014; 37(4):291-5. PubMed ID: 25096804
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.
    Li J; Milne RW; Nation RL; Turnidge JD; Smeaton TC; Coulthard K
    J Antimicrob Chemother; 2004 May; 53(5):837-40. PubMed ID: 15044428
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate.
    Imberti R; Cusato M; Accetta G; Marinò V; Procaccio F; Del Gaudio A; Iotti GA; Regazzi M
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4416-21. PubMed ID: 22687507
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Successful Colistin Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infection Using a Rapid Method for Determination of Colistin in Plasma: Usefulness of Therapeutic Drug Monitoring.
    Yamada T; Ishiguro N; Oku K; Higuchi I; Nakagawa I; Noguchi A; Yasuda S; Fukumoto T; Iwasaki S; Akizawa K; Furugen A; Yamaguchi H; Iseki K
    Biol Pharm Bull; 2015; 38(9):1430-3. PubMed ID: 26155936
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses.
    Marchand S; Lamarche I; Gobin P; Couet W
    J Antimicrob Chemother; 2010 Aug; 65(8):1753-8. PubMed ID: 20507861
    [TBL] [Abstract][Full Text] [Related]  

  • 67. To increase or decrease dosage of antimicrobials in septic patients during continuous renal replacement therapy: the eternal doubt.
    Wong WT; Choi G; Gomersall CD; Lipman J
    Curr Opin Pharmacol; 2015 Oct; 24():68-78. PubMed ID: 26667969
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis.
    Durakovic N; Radojcic V; Boban A; Mrsic M; Sertic D; Serventi-Seiwerth R; Nemet D; Labar B
    Intern Med; 2011; 50(9):1009-13. PubMed ID: 21532223
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effective removal of colistin methanesulphonate and formed colistin during intermittent haemodialysis in a patient infected by polymyxin-only-susceptible Pseudomonas aeruginosa.
    Luque S; Sorli L; Li J; Collado S; Barbosa F; Berenguer N; Horcajada JP; Grau S
    J Chemother; 2014 Apr; 26(2):122-4. PubMed ID: 24090909
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.
    Mohamed AF; Cars O; Friberg LE
    J Antimicrob Chemother; 2014 May; 69(5):1350-61. PubMed ID: 24474432
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats.
    He H; Li JC; Nation RL; Jacob J; Chen G; Lee HJ; Tsuji BT; Thompson PE; Roberts K; Velkov T; Li J
    J Antimicrob Chemother; 2013 Oct; 68(10):2311-7. PubMed ID: 23749953
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Systemic pharmacokinetics and safety of high doses of nebulized colistimethate sodium in critically ill patients with hospital-acquired and ventilator-associated pneumonia.
    Benítez-Cano A; de Antonio-Cuscó M; Luque S; Sorlí L; Carazo J; Ramos I; Bermejo S; Campillo N; Horcajada JP; Samsó E; Grau S
    J Antimicrob Chemother; 2019 Nov; 74(11):3268-3273. PubMed ID: 31495877
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
    Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Effect of continuous renal replacement therapy on plasma concentration, clinical efficacy and safety of colistin sulfate].
    Peng D; Zhang F; Li Z; Lyu P; Guo Z; Chen Y; Zhao J; Niu J; Guo B; Jia W; Jiang X; Li X; Qi S; Qin B; Shao H
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Jan; 35(1):88-92. PubMed ID: 36880245
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
    Wenzler E; Butler D; Tan X; Katsube T; Wajima T
    Clin Pharmacokinet; 2022 Apr; 61(4):539-552. PubMed ID: 34792787
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A Population WB-PBPK Model of Colistin and its Prodrug CMS in Pigs: Focus on the Renal Distribution and Excretion.
    Viel A; Henri J; Bouchène S; Laroche J; Rolland JG; Manceau J; Laurentie M; Couet W; Grégoire N
    Pharm Res; 2018 Mar; 35(5):92. PubMed ID: 29532176
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Levetiracetam dosing in patients receiving continuous renal replacement therapy.
    Chaijamorn W; Charoensareerat T; Rungkitwattanakul D; Phunpon S; Sathienluckana T; Srisawat N; Pattharachayakul S
    Epilepsia; 2021 Sep; 62(9):2151-2158. PubMed ID: 34247386
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Shedding light on the use of colistin: still gaps to be filled].
    Luque S; Grau S; Berenguer N; Horcajada JP; Sorlí L; Montero MM; Salas E
    Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):287-96. PubMed ID: 21440335
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.